NCT06160791View on ClinicalTrials.gov

Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

PHASE2SuspendedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions
Hemophagocytic Lymphohistiocytoses
Interventions
DRUG

Ruxolitinib

Administered Orally (PO)

DRUG

Etoposide

Administered IV

DRUG

Dexamethasone

Administered PO or IV

PROCEDURE

Non-interventional Imaging

Participants undergo abdominal ultrasound and/or magnetic resonance imaging (MRI)

PROCEDURE

Research Biopsy

Bone marrow biopsy and lymph node biopsy will be obtained during screening and as clinically indicated throughout the trial.

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

Jerry Lee, MD, MSc, MPhil

OTHER

NCT06160791 - Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) | Biotech Hunter | Biotech Hunter